Table 1 Demographics and clinical characteristics of NAFLD, HBV and HCV cases.

From: Improved survival after treatments of patients with nonalcoholic fatty liver disease associated hepatocellular carcinoma

 

NAFLD

HBV

HCV

P value

Males n, %

59 (47)

135 (79)

97 (61)

<0.0010

Mean age at HCC dx ± SD

64.8 ± 8.5

57.7 ± 12.7

65.9 ± 10.3

<0.0001

Hispanic ethnicity, n (%)

52 (42)

2 (1)

29 (18)

<0.0010

T2D and glucose intolerance, n (%)*

86 (69)

21 (13)

28 (18)

<0.0001

Decompensation, n (%)

HE

31 (25)

19 (11)

10 (6)

<0.0001

Ascites/volume overload

45 (36)

3 (2)

25 (15)

<0.0001

Child-Pugh Score*

A

44 (43)**

120 (71)

121 (77)

<0.0010

B

35 (34)

41 (24)

30 (19)

 

C

10 (10)

9 (5)

6 (3.7)

 

Missing data

11

0

2

 

Median INR (IQR) *

1.2 (11–1.3)

1.1 (1–1.2)

1.1 (1.1–1.3)

0.0001

Median AST (IQR) *

45 (33–60)

65 (35–113)

84 (49–128)

<0.0001

Median ALT (IQR) *

32 (21–45)

54 (32–84)

64 (38–114)

<0.0001

Median bilirubin (IQR) *

1.2 (0.7–2.3)

0.9 (0.7–1.6)

1.1 (0.8–1.6)

0.0246

Screened for HCC, n (%)

59 (47)

79 (47)

95 (58)

0.1053

Family history HCC, n (%)

11 (9)

42 (25)

8 (5)

<0.0001

  1. *at the time of HCC diagnosis;** excludes patients without cirrhosis (see Table 3). T2D = type 2 diabetes; HE = hepatic encephalopathy; INR = International National Ratios; AST = aspartate aminotransferase; ALT = alanine aminotransferase; HCC = hepatocellular carcinoma; IQR = interquartile range.
Back to article page